Significant shareholders:
| Shareholder/Beneficial Owner | Shares | % ISC |
|---|---|---|
| Invesco | 152,425,639 | 15.85 |
| Lombard Odier Investment Managers | 141,593,743 | 14.73 |
| T Rowe Price Global Investments | 93,927,465 | 9.77 |
| Canaccord Genuity Wealth Management | 85,007,125 | 8.84 |
| Hargreaves Lansdown, stockbrokers | 60,782,047 | 6.32 |
| Dr Andrew Nelson* | 46,266,881 | 4.81 |
| Interactive Investor | 46,118,540 | 4.80 |
as at 30 June 2023
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 961,386,955 Ordinary shares.
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 36.3%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: The Company holds 4,115 Ordinary Shares in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings.